Serious questions need answering around the supply of ventilators during the COVID-19 crisis, with some states making false cries for help, others being over-supplied, raising doubts about the reliability of decision-making over vital supplies during the pandemic. This was the message of former United States Deputy Secretary of Health and Human Services, Eric Hargan, in his keynote address on Sunday morning.

“When we did [supply ventilators in response to demand] we saw deaths start rising,” he told the audience. New Orleans turned to more ‘creative’ measures and proneing when ventilators were in short supply; yet preliminary findings suggest it came off better than New York that had more than it needed, according to Mr. Hargan.

Mr. Hargan was involved in swiftly developing the necessary regulatory and policy protections under immense time pressure to mitigate the impact of the pandemic, tackling supply chain issues, workforce shortages, economic losses and resource constraints. As the largest department in the federal government, Health and Human Services and has an annual budget in excess of $1.3 trillion and over 80,000 employees.

Mr. Hargan served on the Board of Operation Warp Speed, started in March 2020 as the federal effort to catalyze the development of COVID-19 vaccines. He coordinated the first major Warp Speed project, starting in Spring of 2020. Here at the Annual Meeting, he recalled events around provision of care for patients and clinicians, at a time of high demand and low supply, in particular personal protective equipment (PPE) and provision of ventilators for ICU patients.

“It is incumbent upon us to learn from these events, and whether our decisions were useful or not in preparation for the next one.”

Eric Hargan

Martine Rothblatt delivered her featured lecture Doing the impossible: time and time again on Sunday at the Annual Meeting to captivated audience. Dr. Rothblatt, who is Chairperson and CEO of United Therapeutics Corporation (UT), is responsible for several innovations in aviation and architecture. UT is also in pre-clinical development of manufactured kidneys, hearts and 3D printed autologous lungs to be delivered via autonomously flown electric vertical takeoff and landing (eVTOL) systems.

Martine Rothblatt delivered her featured lecture Doing the impossible: time and time again on Sunday at the Annual Meeting to captivated audience. Dr. Rothblatt, who is Chairperson and CEO of United Therapeutics Corporation (UT), is responsible for several innovations in aviation and architecture. UT is also in pre-clinical development of manufactured kidneys, hearts and 3D printed autologous lungs to be delivered via autonomously flown electric vertical takeoff and landing (eVTOL) systems.
Ventilators – help or harm?

The federal government has a stockpile which often sits unused but at other times is insufficient. Decisions around how much to supply, and to whom, was a question dependent on having the correct information. Such reliable information, said Mr. Hargan, was often in short supply in the surge scenario.

“We had a few thousand ICU beds in the stockpile, but we needed more. ICU beds are expensive, so we don’t buy endless amounts and have them sit there empty,” he said.

Ventilator use over the pandemic is a particular case in point. Research is needed to look at to what extent, and when, the supply of ventilators was suddenly made available, said Mr. Hargan. In a crisis setting, in addition to the non-crisis scenario, there is a big question around which interventions are helpful, and which ones are harmful. “If we have an endless number of ICU beds and everyone is hooked up to ventilators, is this a good thing or a bad thing from a public health point of view, will it help or harm patients?”

Mr. Hargan highlighted that these were hard decisions to make, but the pandemic required that they moved quickly. “Essentially, there were enough clinical people making the decision to determine whether such interventions should be supplied? This needs to be considered from a legal and administrative standpoint.”

He went on to highlight when a government

“Federal government has to rely on state government officials to give us a reality check on what is needed.”

Eric Hargan

officially wrongly told a reporter how many ventilators the government had, and in response the governor of New York City asked for more ventilators than they had allocated for national supply. “New York didn’t end up using the ventilator supply it had, and it didn’t use the 2,000 ICU beds they had. In fact, New York had a greater supply than the United Kingdom overall,” he recalled.

Regarding ventilators, New Orleans did not have many because it is a relatively poor state, so they developed a lot of techniques for managing patients, for example proning, and other creative responses. In contrast, New York had a lot of ventilators and they used the ventilators, “But when I left office in 2021, early results suggested that New Orleans by and large fared better than New York. These are the numbers that speak for themselves,” he said.

“When this New Orleans responded with non-ventilator interventions or not? Was it a characteristic of the population? We need to break down these results to find out if ventilators were a negative intervention for these patients, particularly for the less severe.

In light of the fact that we were dealing with an unknown virus and unknown disease, a decision has to be made in the heat of the moment. But the question is are we going to learn from what happened in the middle of all this for the next time?”

Prioritizing COVID-19 or other surgeries – lockdown never again!

Another question that emerges now that the pandemic has started to subside, is how much non-emergency care was canceled. The question to ask is how do we prioritize these patients if there is another crisis?

The next time a pandemic hits, governors and mayors may not take the same actions again, Mr. Hargan pointed out. There were damaging effects of the lockdown, for example developmental issues with children, mental health, behavioral health, and rising drug use, as well as around the lack of childhood vaccinations over the pandemic. “This raises questions about how we deal with a surge capacity for infectious disease. In the future, they might decide not to do lockdown but continue with the same level of cancer care, heart disease, screening and all the other areas of medicine,” he said.

“I spoke to a lot of people after I left office, and they said never lockdown, never again. We will never support this. This is a widespread view from hospital side of things.”

Next time, the response will need to be much more “complicated”, he notes. Lockdowns were widespread and lasted for a significant time, adding, that “the effects are now appearing such that they will avoid this response next time, in many cases.”

There are going to be a lot of questions for the medical and research community, for which equipment both in the US and Canada during this surge capacity. “This is a big problem. Federal government has to relearn on state government officials to give a reality check on what is needed.”

The problem, he said, was that people had to react to reports that came out of nowhere, for example a large city called them in the middle of the night and said they needed 500 ventilators “before 8:00 AM tomorrow due to a surge.” At 2:00 AM, calls were received to say the former information was false. “At this point, we were already getting pallets to move ventilators to the city. By the time this information arrived lots of people and resources had already been committed,” said Mr. Hargan.

He explained that they saw signals like this coming in all the time. New York was an example, of “wanting everything now.” But often, he stressed, upon checking need with various health governors, they received a reality check of what was needed.

“Sometimes, we had to make a decision about supplies based on a story or a call that came in. This is the dilemma going forward how do we separate the signals from the noise, the truth from the false information? There were lots of signals going on – for example images of nurses in trash bags that were fake. There were political statements being made. At other times, a hospital administrator would say they’re going to run out of an item in two weeks, while other places were running out in three days. We had to prioritize. We have to ask where is this information from, who’s giving it to us, is it real, is it claims data or clinical data?”

Indeed, there were a lot of emotional reactions, not based on data. “Panic kills” said Mr. Hargan. “Emotion is a good thing and a bad thing, but in many cases it was taking us away from the truth. And, when it comes down to resource allocations, and we are stretched, then we are making decisions based on reality. This isn’t an area for over-reacting.”

Eric Hargan

answers will be needed before the next time, and before decisions are made.

During yesterday’s session, the moderator asked whether the federal government might take a more effective look at the social determinants of health in preparation for the next pandemic, given that some of these policies were already “behind” before the pandemic started, and were in need of correction.

Mr. Hargan replied, “We all know that social determinants have an effect. The question for federal government is how to re-orient, and fund, the various projects around social determinants, because these clearly had huge effects. If you look at the characteristics of the population that was worst affected, whether obesity, or general health, there had a huge effect on what happened during COVID-19.”

“With COVID-19, the mortality curve went straight up toward the overweight, toward those who had comorbidities, immunosuppressed, while the young experience very little.”

Reality check – political statement or real need?

Rakesh C. Arora (Winnipeg, Canada), asked Mr. Hargan about supply of equipment, in particular ECMO. “There was a lot of resource, but it was not distributed in a way that people could access it. There was a lack of coordination over equipment both in the US and Canada during this pandemic. How will that be different next time?”

Mr. Hargan responded, saying that it was important to understand the signals coming in for demand, and to separate those from the noise. “This is a big problem. Federal government has to rely on state government officials to give a reality check on what is needed.”

The problem, he said, was that people had to react to reports that came out of nowhere, for example a large city called them in the middle of the night and said they needed 500 ventilators “before 8:00 AM tomorrow due to a surge.” At 2:00 AM, calls were received to say the former information was false. “At this point, we were already getting pallets to move ventilators to the city. By the time this information arrived lots of people and resources had already been committed,” said Mr. Hargan.

He explained that they saw signals like this coming in all the time. New York was an example, of “wanting everything now.” But often, he stressed, upon checking need with various health governors, they received a reality check of what was needed.

“Sometimes, we had to make a decision about supplies based on a story or a call that came in. This is the dilemma going forward how do we separate the signals from the noise, the truth from the false information? There were lots of signals going on – for example images of nurses in trash bags that were fake. There were political statements being made. At other times, a hospital administrator would say they’re going to run out of an item in two weeks, while other places were running out in three days. We had to prioritize. We have to ask where is this information from, who’s giving it to us, is it real, is it claims data or clinical data?”

Indeed, there were a lot of emotional reactions, not based on data. “Panic kills” said Mr. Hargan. “Emotion is a good thing and a bad thing, but in many cases it was taking us away from the truth. And, when it comes down to resource allocations, and we are stretched, then we are making decisions based on reality. This isn’t an area for over-reacting.”

“We need data dashboards, and we need to ask how they’re made up and where the sources are. And ask if they get down to reality, and show what is actually taking place.”
NEW

100+ MICRO fasteners in patients

INTRODUCING THE NEXT COR-KNOT® MICRO

EXTREME RELIABILITY
Pre-loaded titanium fastener 6-0, 7-0, or 8-0 polypropylene

BOOTH 1811 SOLUTIONS®
Lung cancer screening in 2022

Betty Tong from Duke University Medical Center, Durham, NC, USA, talked the topic of lung cancer screening on Saturday afternoon, walking the audience through the current screening landscape, unmet needs, and strategies to improve adherence. AATS Daily News spoke to Dr. Tong to gather her brief perspectives on the status of lung cancer screening in 2022.

While studies such as the National Lung Screening Trial (NLST) and NELSON have proven that lung screening can have a dramatic effect on saving lives, don't screening rates still have a long way to go? Yes, that's true. The latest studies show that national screening rates are hovering around 5%—that is, only 5% of screen-eligible people are getting a low-dose computed tomography (LDCT) scan of the chest. The newest United States Preventive Services Taskforce (USPSTF) guidelines have a lower age and smoking history requirement. With this, an even larger number of individuals are eligible for LDCT screening, and it remains to be seen if there is a proportional change in the number of people who actually do get their CT scan.

What are your thoughts on improper follow-up (according to guidelines), especially in self-paying individuals?

Nationally, adherence to annual screening for people with normal or benign baseline CT scans ranges from 12 to 91%, with the mean around 55%. In the setting of the COVID pandemic with specific safety and cleaning protocols, what’s the real-world evidence? Right now there are few studies on this topic. Probably the best one was published in CHEST recently. It might surprise you to know that screening rates were reasonably stable, albeit low, in 2020 compared to 2019. Our colleagues in Italy showed that screening can be done safely and effectively, and help them remain adherent to guidelines for follow-up. Education of patients, as well as our colleagues, is paramount. In fact, it’s a really exciting time for lung cancer screening. There are studies underway evaluating the role of serum biomarkers, or ‘liquid biopsy,’ as well as artificial intelligence and radiomics, as possible adjuncts to low-dose CT scans.

Betty Tong

Are there misconceptions about lung screening at both patient- and provider level that should be better explored?

Yes there are! Several studies have shown that there is a lack of buy-in from providers. For example, the USPSTF and Centers for Medicare & Medicaid Services have endorsed and approved LDCT screening since 2015 and 2019, respectively, based on Level 1 evidence in the NLST showing a reduction in lung mortality with LDCT screening. But despite this, the American Academy of Family Physicians, did not recognize or endorse LDCT screening until the last year or so. Some of my colleagues have also demonstrated that there are patient-related barriers to both initial screening, as well as compliance with annual follow-up.

What’s important going forward?

While some really important work has been done to demonstrate the efficacy of LDCT screening for lung cancer, we must continue in our efforts to increase screening uptake in appropriate individuals.

Are there unmet needs, and strategies to improve adherence.

Dr. Tong has once again made a major contribution in changing the way we think about a congenital condition involving the pulmonary arteries. He will highlight innovation and educate on the extent of correction that can be achieved, including his unique approach to treating this condition.

Christopher Caldarone

Are there any misconceptions about lung screening at both patient- and provider level that should be better explored?

Yes, that's true. The latest studies show that national screening rates are hovering around 5%—that is, only 5% of screen-eligible people are getting a low-dose computed tomography (LDCT) scan of the chest. The newest United States Preventive Services Taskforce (USPSTF) guidelines have a lower age and smoking history requirement. With this, an even larger number of individuals are eligible for LDCT screening, and it remains to be seen if there is a proportional change in the number of people who actually do get their CT scan.

What are your thoughts on improper follow-up (according to guidelines), especially in self-paying individuals?

Nationally, adherence to annual screening for people with normal or benign baseline CT scans ranges from 12 to 91%, with the mean around 55%. In the setting of the COVID pandemic with specific safety and cleaning protocols, what’s the real-world evidence? Right now there are few studies on this topic. Probably the best one was published in CHEST recently. It might surprise you to know that screening rates were reasonably stable, albeit low, in 2020 compared to 2019. Our colleagues in Italy showed that screening can be done safely and effectively, and help them remain adherent to guidelines for follow-up. Education of patients, as well as our colleagues, is paramount. In fact, it’s a really exciting time for lung cancer screening. There are studies underway evaluating the role of serum biomarkers, or ‘liquid biopsy,’ as well as artificial intelligence and radiomics, as possible adjuncts to LDCT scans.

Betty Tong

“Adherence to screening guidelines and follow-up is suboptimal right now. One way to improve this would be to provide screening through a centralized program. This, in and of itself, has been shown to be strongly predictive of patient adherence.

What about a lack of imaging facilities for proper screening?

Our group’s prior research has shown that geographic access to CT scanners varies widely throughout the country. There are some patients who live more than 200 miles from a CT facility that is accredited by the American College of Radiology. With inflation and gas prices today, it’s not likely at all that these patients are going to take the time, or pay the money, to get to that scanner for a screening study.

Are there particular demographics failing to receive sufficient screening for lung cancer? What’s the fallout?

Uninsured and underserved patients are likely not being screened at rates that insured patients are being screened. Currently, coverage for LDCT screening is not mandatory for patients with Medicaid. Unfortunately, these patients have smoking rates that are more than twice those of patients with private insurance and Medicare. So, it’s an additive process where one problem may be compounded by another.

Shared decision-making is a core component of lung cancer screening, but are their challenges, especially in terms of consistency? Absolutely. In our institutional experience, there is wide variability in documentation of shared decision-making, much less how it’s delivered.

Many would assume that COVID-19 will have had a rather detrimental impact on lung cancer screening. What’s the real-world evidence?

Right now there are few studies on this topic. Probably the best one was published in CHEST recently. It might surprise you to know that screening rates were reasonably stable, albeit low, in 2020 compared to 2019. Our colleagues in Italy showed that screening can be done safely and effectively, and help them remain adherent to guidelines for follow-up. Education of patients, as well as our colleagues, is paramount. In fact, it’s a really exciting time for lung cancer screening. There are studies underway evaluating the role of serum biomarkers, or ‘liquid biopsy,’ as well as artificial intelligence and radiomics, as possible adjuncts to LDCT scans.

Betty Tong

“Geographic access to CT scanners varies widely throughout the country. There are some patients who live more than 200 miles from a CT facility.”
A minimally invasive mitral masterclass was featured on Sunday morning, where a number of invited experts gathered to present their perspectives on this important branch of valvular care. In his talk, Volkmar Falk (German Heart Center Berlin, Germany) offered some ‘pearls and pitfalls’ of neochordal reconstruction.

Chordal replacement, or the so-called ‘respect approach’, harnesses artificial neochordae to resuspend prolapsed segments of the affected leaflet. Conversely, the ‘resect approach’ involves resection of the diseased leaflet segment, after which the remaining segments are sutured together.

“Resection techniques are less forgiving. An imperfect result is difficult to correct as the amount of remaining tissue is already reduced.”  

Volkmar Falk

In contrast, leaflet-preserving techniques using neochordae provide a large coaptation area that reduces the stress on the leaflets, while maintaining leaflet mobility, noted Professor Falk. “Some studies found lower inflow gradients with these so-called ‘respect’ techniques,” he said.

“Resection techniques are less forgiving. An imperfect result is difficult to correct as the amount of remaining tissue is already reduced.”

Volkmar Falk

In his talk to AATS Daily News, Professor Falk relayed the modern consensus that the ‘perfect’ mitral valve repair includes a line of coaptation below the annulus, at least 2:1 anterior/posterior leaflet ratio (better 3:1), coaptation length at least 4–8 mm, and no causal inflow gradient.

While both resection and artificial chordae are methods to achieve such a repair, resection has been associated with a number of challenges, including restoration of normal coaptation length, mis-sizing of the valve orifice, and the limiting of re-repair options later on. “Resection techniques such as triangular or quadrangular resection of the posterior leaflet can effectively reduce leaflet height, and correct prolapse,” said Professor Falk. “However, after such a correction, often the posterior leaflet is largely immobile, and the coaptation depth is limited.

“In addition, the lack of abundant tissue typically leads to the implantation of smaller annuloplasty rings. Also, resection techniques are less forgiving. An imperfect result is difficult to correct as the amount of remaining tissue is already reduced.”

Volkmar Falk

References
Proposals for a new AATS consensus document on the use of mechanical circulatory support (MCS) for lung transplantation will be introduced this afternoon by Matthew G. Hartwig, Associate Professor of Surgery, Division of Thoracic Surgery at the Duke University Health System (NC, USA). Dr. Hartwig is a general thoracic surgeon with a particular interest in end-stage lung disease and lung transplantation. “In order to provide the best care possible for our patients with lung failure or requiring lung transplantation, thoracic surgeons require knowledge and expertise in mechanical devices that can support the failing lung,” he told AATS Daily News.

According to Dr. Hartwig, MCS for lung or heart failure has changed considerably over the years. “With improvements in pump technologies, requisite cannulas and tubing, and miniaturization of circuits (for example), the use of these devices is changing rapidly,” he said. “Those improvements, and the way in which they are used, mean there are relative merits of different devices. There is a suggestion that gaps in practice for the nuances of using MCS exist, and that the transplant community lacks clear, comparative understanding of the techniques.”

Dr. Hartwig is one of the co-chairs of the AATS expert committee working alongside surgeons such as Victor van Berkel from the University of Louisville (MO, USA). He will explain the thinking, therefore, behind the consensus document. “The AATS believes it’s important to provide the latest guidance on how to best use modern MCS to benefit our patients before, during, and after lung transplantation,” he said. “Establishing an expert consensus document would be the most appropriate way to meet our needs.”

“The AATS believes it’s important to provide the latest guidance on how to best use modern mechanical circulatory support to benefit our patients before, during, and after lung transplantation.”

Matthew G. Hartwig

Dr. Hartwig is on the steering committee of this so-called ECLS (Extracorporeal Life Support Organization, ELSO) before, during and after lung transplantation (ECLS) registry, that is led by Gabriel Loor of Baylor College of Medicine (TX, USA). The ECLS registry currently collects data from seven US and two European centers. “It is exciting that hundreds of patients have already been enrolled in the ECLS LTx registry, and from this work we hope to learn how best to use these technologies,” he said.

Dr. Hartwig said one of the biggest challenges in this field is the lack of high-level evidence to support current practices. “This remains a relatively low-volume, niche field where individual centers lack sufficient volumes to perform well-controlled studies,” he explained. “That, combined with the multiple variations in how MCS can be performed, remains the Achilles’ heel to better reach consensus.”

Collecting data within such a document is an important first step in the quest for consensus, and should help to form the basis for future research efforts in this space, said Dr. Hartwig. “Like the ECLS LTx registry, the community would benefit greatly from a multicenter clinical trials organization and infrastructure through which we could perform prospective and randomized clinical trials that provide the level of evidence to clearly guide practice and build consensus,” he added.

For example, one persistent and unresolved concern with MCS in lung transplantation remains what optimal form of MCS, if any, should be utilized during the actual explant and implantation of the donor lungs. “There continues to be strong disagreement among those who believe that their chosen technique – be it cardiopulmonary bypass, extracorporeal membrane oxygenation, or non-mechanical support – is the optimal choice,” said Dr. Hartwig. A high-quality, prospective, randomized clinical trial would go a long way toward defining the optimal mechanical support, if any exists, for lung transplantation, he said. “This type of study could also go a long way toward helping understand the mechanism of primary graft dysfunction following lung transplantation, and whether the use of mechanical circulatory support would be propagative or protective,” he said.

Of course, reaching consensus might see some pushback, conceded Dr. Hartwig. “Any time a guidelines or consensus document tackles a topic with so much heterogeneity and such a low level of evidence in the literature, there will always be some degree of consternation and disagreement among the readership,” he concluded. “Consensus does not mean unanimity, and therefore real-world practice and opinions will necessarily vary somewhat with that published in the guidelines.”

References
A ProspEctive, Single ARm, Multi–Center Clinical InveStigation to EValuatE the Safety and Effectiveness of AMDS in the TREatment of Acute DeBakey Type I Dissection

Intended Use

AMDS is intended for aortic repair, aortic remodeling, and re-expansion of the intimal flap within the ascending aorta, aortic arch, and into the descending aorta for patients with acute DeBakey type I aortic dissection undergoing open surgical repair within 0 to 14 days after diagnosis.

Visit Booth #1623 to learn more about this Clinical Trial.
The AATS Foundation

The AATS Foundation honored awardees, mentors, donors, and partners at the AATS Foundation Reception on Sunday. Each year, the Foundation honors incoming awardees and welcomes back a number of former recipients whose careers have been positively impacted by the funding they received. Thanks to the support of Foundation constituents, educational and research initiatives continue to thrive. Donors and partners are making a significant impact on the careers of future leaders.

Dr. David Adams, President of the AATS Foundation, shared details about the Get Together, Give Together campaign, a special initiative in recognition of the AATS 102nd Annual Meeting. Reiterating the importance of giving back, Dr. Adams thanked those wearing donor pins this year – a true testament to the generosity of the community. The engagement and support of donors and partners is critical to the Foundation’s ongoing success.

AATS Foundation leadership proudly shared information on the unique program offerings including the Cardiac Surgical Robotics Program, Valerie Rusch Mentored Career Development Award, and the newly established Honoring Our Mentors Program recognizing Professor Alain Carpentier. AATS President-Elect, Dr. Yolonda Colson reflected on the overwhelming support of the Rusch program, highlighting the enormous respect for Dr. Rusch and the impact of her contributions to thoracic surgery and the importance of supporting women in the field globally.

Dr. Rusch stated, “It is my firm belief that we have the obligation to give back to others around the world who may not have had that privilege. I look forward not only this year, but in future years, to seeing this award work to that end to promote transfer of knowledge in career development for younger surgeons in somewhat less fortunate environments, and to help us build the specialty around the world.”

The reception was an opportune time to recognize awardees, who are the future of the cardiothoracic field, along with donors, whose generous contributions ensure that the mission of the Foundation is fulfilled.

Please visit aatsfoundation.org to make a gift, learn more about our programs, and view award opportunities currently accepting applications.

Member for a Day Session

Saturday, 4:00–6:00 PM

On Saturday, May 14, Member for a Day awardees and trainees joined us for a two-hour session with a panel of AATS members, AATS leadership, and senior fellows. Faculty offered guidance to trainees concerning pathways in cardiothoracic surgery, why they love being cardiothoracic surgeons, as well as what it means to be a part of the American Association for Thoracic Surgery. The session was followed by a reception offering light appetizers and beverages for socializing and networking with AATS members, mentors, and trainees.
Better Outcomes don’t always come at high costs

**LSS**
Longitudinal Sternal Stabilization

- **5.6x** fewer patients with DSWls\(^1\)
- **3-Day** reduction in length of stay\(^1\)
- **2.1x** more patients healed at 90 days post-op\(^1\)
- **Zero Cost** re-entry

---

A n important trial evaluating fractional flow reserve (FFR)-
guided percutaneous coronary intervention (PCI) compared with
coronary artery bypass graft (CABG) surgery will be under discussion
this morning by William F. Fearon, a professor of medicine and the director of interventional cardiology at Stanford University School of Medicine, and the Chief of the Cardiology Section at the Palo Alto VA Health Care System (CA, USA).

Professor Fearon told AATS Daily News about his role as principal investigator for the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial.

During the session, Professor Fearon will discuss the design of and rationale behind the trial, noting that, until recently, patients with three- vessel coronary artery disease had been found to have better outcomes with CABG than with PCI. Large, randomized trials have shown improved outcomes in patients with three-vessel coronary artery disease when coronary revascularization was performed with CABG compared to PCI. They include the 1,900-strong Future Revascularization Evaluation in Patients with Coronary Disease (FREEDOM) trial.

“Surgeons will likely feel that CABG is better in all cases, while interventional cardiologists will likely feel that there is a role for PCI in patients with multivessel disease,” said Professor Fearon.

FFR-guided PCI. The incidence of death, myocardial infarction, or stroke was 7.3% in the FFR-guided PCI group, and 5.2% in the CABG group. The incidences of major bleeding, arrhythmias, and acute kidney injury were higher in the CABG group than in the FFR-guided PCI group.

Professor Fearon added that FFR-guided PCI with current generation drug-eluting stents did not meet the criterion for non-inferiority when compared with CABG. “We discovered that outcomes after PCI have improved significantly using FFR and newer stents when compared to historical control. Outcomes after CABG have also improved,” said Dr. Fearon. “Finally, the difference in outcome between the two strategies has disappeared.”

Both patients and physicians now have more contemporary data in order to make informed and shared decisions, reasoned Professor Fearon.

“Surgeons will likely feel that CABG is better in all cases, while interventional cardiologists will likely feel that there is a role for PCI in patients with multivessel disease,” he explained.

Professor Fearon said he’d like to see further studies into CABG. “Hybrid procedures combining minimally invasive CABG plus PCI to traditional CABG would be interesting to study.”

Offering his take-home message for the FAME 3 trial: “We now have updated data regarding clinical outcomes and quality of life after PCI and CABG in patients with multivessel coronary artery disease, which can help guide decisions regarding the optimal strategy for a particular patient.”

References
4. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for Multivessel Coronary Artery Disease (BEST) trials. Second-generation drug-eluting stents have improved early- and late outcomes, leading to lower rates of associated stent thrombosis, spontaneous myocardial infarction, restenosis, and death than first- generation drug-eluting stents. “But studies in which PCI is guided by measurement of FFR have been lacking,” said Professor Fearon. The thinking is that FFR is an index, measured with a coronary pressure wire, that provides a more accurate assessment of the hemodynamic significance of a coronary stenosis than an angiogram alone. Professor Fearon’s FAME 3, therefore, is a multicenter, international, non-inferiority trial, with a total of 1,900 patients undergoing randomization at 48 centers. Patients with three-vessel coronary artery disease were randomly assigned to undergo CABG or FFR-guided PCI with current generation zotarolimus-eluting stents. The primary end point was the occurrence of a major adverse cardiac or cerebrovascular event at one year, defined as death from any cause, myocardial infarction, stroke, or repeat revascularization.

Professor Fearon will discuss the main results from the trial during his talk. Giving a snapshot ahead of time, he noted that one-year incidence of the composite primary end point was 11% among patients randomly assigned to undergo FFR-guided PCI, and 6.6% among those assigned to undergo CABG – findings that were not consistent with non-inferiority of FFR-guided PCI. The incidence of death, myocardial infarction, or stroke was 7.3% in the FFR-guided PCI group, and 5.2% in the CABG group. The incidences of major bleeding, arrhythmias, and acute kidney injury were higher in the CABG group than in the FFR-guided PCI group.

Professor Fearon added that FFR-guided PCI with current generation drug-eluting stents did not meet the criterion for non-inferiority when compared with CABG. “We discovered that outcomes after PCI have improved significantly using FFR and newer
Dealing with bullies, bias, and burnout was the order of business on Saturday during the Cardiothoracic Careers College, with Jennifer Romano, a congenital heart surgeon at the University of Michigan (MI, USA) and the Second Vice President to the Society of Thoracic Surgeons, stepping up to the podium to share her insights. Her practice encompasses all elements of pediatric cardiac surgery, with a focus on neonatal surgery and hybrid interventions. "I am also one of the very few women in my specialty, and will serve as the first female president," she told AATS Daily News.

"By virtue of the hurdles that I have overcome to get to my current position, I have faced all of the challenges discussed in this session," she added. "We are so busy with academic efforts, patient care, and advancement that these ‘softer skills’ have historically not received the attention they are due," she said. "Certainly, components are opinion," she added. "There may be many strategies individuals can use." The greatest challenge is helping people make these concepts a priority, said Dr. Romano. "We are not busy enough with academic efforts, patient care, and advancement that these ‘softer skills’ have historically not received the attention they are due," she said. "We cannot truly be the best to our families and patients if we are struggling in a difficult work environment, or overcome with commitments and expectations," she said.

"Just raising awareness is enough, therefore. ‘It’s important to determine when you can make a difference, and when you will be banging your head against the wall.’"

Jennifer Romano

In the session on Saturday, Dr. Romano spoke about the importance of self-awareness, personal reflection, friends and feedback, and an ongoing commitment to self-improvement. "Some of this is about picking your battles," she advised. "It’s important to determine when you can make a difference, and when you will be banging your head against the wall. I am certainly not an expert – rather a lifelong learner and a survivor!"

The epidemic of burnout among physicians is on the rise, and the recent pandemic has only added to the stressors. Even before the pandemic, national data suggested that 44% of US physicians experience symptoms of burnout, characterized by emotional exhaustion and/or de-personalization, at least weekly. Medical errors are then a risk. "We cannot truly be the best to our families and patients if we are struggling in a difficult work environment, or overcome with commitments and expectations," she said.

Dr. Romano added that she did not think it is controversial to talk about such topics. "Certainly, components are opinion," she added. "There may be many strategies individuals can use." The greatest challenge is helping people make these concepts a priority, said Dr. Romano. "We are so busy with academic efforts, patient care, and advancement that these ‘softer skills’ have historically not received the attention they are due," she said. "I asked me to write my obituary as if it was tomorrow," she said. "She asked me if it would say what I wanted my legacy to truly be. It was a sobering exercise that helped to rebalance my priorities."
Abstract

Objective: In preclinical studies, we have demonstrated that cold static preservation (CSP) at 10°C is an effective and reliable strategy for prolonging (~24h) preservation of pulmonary grafts, with underlying protective mechanisms related to the maintenance of mitochondrial health (Science Trans Med, 2011). Here, we report on a prospective multi-center clinical trial designed to investigate the feasibility of intentionally prolonging CSP at 10°C to avoid overnight (10pm - 6am) lung transplants.

Methods: To date, 60 consented patients have been enrolled in this prospective, non-randomized, single armed, multi-center study (n=60 target, NCT04649593). Donors with cross clamp times between 6pm and 9am were able to be enrolled in the study with the earliest allowed transplant starting time of 10pm. Donor exclusion criteria included the need for ex vivo lung perfusion, while recipient exclusion criteria included re-transplantation and multi-organ transplantation. Lungs meeting study criteria were retrieved and transported in the usual fashion using a cooler with ice. Immediately upon arrival to the transplant hospital, lungs were transferred to a 10°C temperature-controlled refrigerator until implantation. The primary outcome of this study was incidence of SHLT Primary Graft Dysfunction (PGD) 3 at 72h, with secondary endpoints including: recipient time on the ventilator, ICU Length of Stay (LOS), hospital LOS, 30-day survival and lung function at 1-year. Outcomes were compared to the study with the earliest allowed transplant starting time of 10pm.

Results: CSP at 10°C to avoid overnight (10pm - 6am) lung transplants. Donor and recipient characteristics, age was 65 years (55 - 74 years). Most patients (97%) received using propensity score matching for medical diagnosis, BMI, survival and lung function at 1-year. Outcomes were compared to the study with the earliest allowed transplant starting time of 10pm.

Conclusions: Intentional prolongation of donor lung CSP using 10°C storage appears to be clinically safe and feasible, with promising results. Avoidance of overnight transplants using this simple approach has the potential to improve transplantation logistics and performance, potentially significantly altering practice in clinical lung transplantation.
栝蒌薤白半夏汤

栝蒌瞿麦丸

栝蒌桂枝汤

栝蒌薤白白酒汤

栝蒌泽泻丸-主要成分

栝蒌桂枝加味汤

栝蒌散(《温病条辨》)

栝蒌桂枝甘草汤

栝蒌桂枝大枣汤

栝蒌承气汤

栝蒌桂枝去桂加茯苓芒硝汤

栝蒌附子大黄汤

栝蒌附子甘草汤

栝蒌薤白半夏汤-主要成分

栝蒌薤白汤

栝蒌薤白白酒汤-主要成分

栝蒌薤白散

栝蒌厚朴汤
‘Live to fight another day’
Maximizing survival after Type A dissection

Opening Tuesday’s Aortic Dissection Masterclass will be Leonard Girardi (Weill Cornell Medicine, New York, NY, USA) who will present his views on how to ‘live to fight another day’ after acute Type A aortic dissection (ATAAD). Dr. Girardi was one of the authors of the 2021 AATS Expert Consensus Document on the surgical treatment of ATAAD, the aim of which was to provide surgeons with a wide range of experience a summary of best practices in dissection diagnosis, operative treatment and follow-up after surgery.

As Dr. Girardi described, the writing group for this document was a well-rounded cohort of very experienced surgeons from centers with a high volume of aortic surgery cases who also have access to the latest innovations and technology to improve the outcomes for these desperately ill patients. AATS Daily News caught up with Dr. Girardi to catch a glimpse of the main messages he will be presenting during his talk.

Perhaps we can start by framing the incidence and devastation of ATAAD? While relatively uncommon, don’t mortality rates escalate quickly with time unless treated, and even then, remain relatively high? While rare relative to more common cardiovascular conditions such as coronary artery disease, ATAAD is being recognized with greater frequency, as cardiologists caring for patients with aneurysms – as well as emergency department physicians - recognize the signs and symptoms of an acute dissection more readily. Despite the initiation of front-line anti-impulse therapy, mortality is still estimated at approximately 1% per hour from the time symptoms begin, until an operation is undertaken. Should malperfusion, shock, contained rupture, and other dissection-related complications arise, the mortality for even a promptly performed operation will escalate dramatically.

Is prompt surgical intervention applicable for the majority of patients? What about those with neurological deficits? And is transfer to a dedicated aortic center reasonable if surgery is not immediately available? Prompt surgical intervention is the treatment of choice for an overwhelming majority of patients presenting with ATAAD, including those with neurologic deficits. Patients with advanced neurologic injury and other significant comorbidity may be considered for palliative care under certain circumstances, but a gratifying percentage of patients presenting with focal deficits will recover neurologic function after ATAAD repair. Transfer to a dedicated center is reasonable if surgery at the center of diagnosis is not available, or if it completely suggests a better opportunity for success in more experienced hands.

Open surgery is the gold standard, and thoracic endovascular aneurysm repair is still in the experimental phase. For patients with prohibitive risk for surgery, an endovascular repair may be appropriate.

What are the essentials when treating ATAAD? Resolution of malperfusion is always a focus of ATAAD treatment. Sometimes it may be appropriate to attempt endovascular resolution of a malperfusion syndrome before open repair. However, those situations mandate significant endovascular experience.

Temperature management is still a topic of discussion, even amongst high-volume aortic surgeons at high-volume aortic centers. Depending on the strategy employed for cerebral protection, deep hypothermia and moderate hypothermia are acceptable strategies. There may be cases in which mild hypothermia is appropriate.

While central aortic and axillary artery cannulation are the most commonly applied arterial cannulation strategies, femoral artery cannulation may at times be appropriate and life-saving.

Getting patients to the operating room as quickly as possible is the appropriate strategy in an overwhelming majority of cases. Rapid diagnosis, initiation of anti-impulse therapy and a safe and simple operation will be life-saving for a majority of the patients requiring surgery for ATAAD.

Attention to detail in the postoperative period is critical to a successful outcome. Prompt treatment of shock, and resolution of malperfusion syndrome, will further reduce the mortality associated with ATAAD repair.

What can be done to lower the chance of late reoperation? Technology and innovations in ATAAD surgery are focused on the reduction of late downstream reoperations. Frozen elephant trunk procedures and other antegrade stent graft deployment strategies have clearly improved downstream aortic remodeling, but have yet to show a definitive benefit for ATAAD late reoperation.

The key to long-term survival is short-term survival, and the application of advanced techniques in the wrong patient by an inexperienced team may not be in the patient’s best interest.”

Leonard Girardi

Preventing late reoperations, or improving long-term survival. Lifelong anti-impulse therapy and serial imaging can help avoid catastrophic late events such as aortic rupture.

What about genetic testing and screening for families to mitigate potential risk? Genetic testing is improving, and in patients with family histories of aortic dissections and/or aneurysms, should be strongly encouraged.

What should take center stage in future studies of ATAAD? The mortality and neurologic injury rates for ATAAD surgery continues to improve, but has a long way to go. Prompt diagnosis and treatment is still the key to improving survival, and the elective repair of aneurysms when approaching guideline-directed diameters for intervention may also prevent ATAAD from occurring.

Technology may be the key to reducing the longer-term need for reinterventions and additional operations.

How would you sum up your key messages here?
I’d refer back to the title of my talk: ‘Live to fight another day’. While the Expert Consensus Document and numerous manuscripts published by the writing group members touch on a myriad of advanced surgical techniques and innovations that are meant to reduce the late morbidity for those surviving the operation, the goal is still a safe and expedient index operation that saves the patient’s life. The key to long-term survival is short-term survival, and the application of advanced techniques in the wrong patient by an inexperienced team may not be in the patient’s best interest.

“Resolution of malperfusion is always a focus of ATAAD treatment. Sometimes it may be appropriate to attempt endovascular resolution of a malperfusion syndrome before open repair. However, those situations mandate significant endovascular experience.”

Leonard Girardi

---

Don’t miss!
High Performance Cardiothoracic Surgery in the Digital Age*
Tuesday, 10:00 AM, Room 309

Program:

Introduction
Speaker: Marc Moon, Bayhill College of Medicine / Texas Heart Institute

Invited Discussions: Mara Antonoff, MD Anderson Cancer Center; Andrew Goldstone, NYU-Columbia
Abstract Presenter: Lauren Barron/ Barnes Jewish Hospital

Building High-Performing Hybrid Teams: What CT Surgery can learn from F35 Fighter Pilots, Formula Racing, and Navy SEALs About Robots, Distributed Work and Cognitive Overload
Keynote: Brian Ferguson/ Arena Labs

Clinical
Speaker: Y. Joseph Wise/ Stanford Hospital

Research
Speaker: David Jones/ Memorial Sloan Kettering

Education
Speaker: Yolonda Colson/ Massachusetts General Hospital

Maximizing performance in cardiothoracic surgery: Where do we go from here?
Speaker: Douglas Johnston/ Cleveland Clinic/ Cleveland Clinic Fireside Chat: How did WFH Change, Worsen, Improve, Accelerate Technology Adoption?
Panelists: David James/ Memorial Sloan Kettering; Yolonda Colson/ Massachusetts General Hospital; Douglas Johnston/ Cleveland Clinic; Brian Ferguson/ Arena Labs (India-CMB)
**Michler® Heart Vent Catheter**

**Designed by Dr. Robert Michler, Montefiore-Einstein Healthsystem**

- **New Product INTRODUCTION**
- **FDA Cleared**

The Michler® Heart Vent Catheter is intended for use in venting the left heart during cardiopulmonary bypass surgery. Uniquely, the device is securely positioned and maintained in the LV by inflating a soft positioning balloon against the mitral annulus/valve.

- Prevent LV distention and unintended LV perforation
- Prevent air ejection from left heart
- Aspiration of air, blood and debris
- Malleable and flexible
- Optimize LV positioning
- Aspiration from both LA and LV
- Diminishes RBC shearing resulting in higher hemoglobin and hematocrit
- Lattice formation diminishes turbulent flow resulting in decreased emboli formation

---

**The Original Cosgrove® Mitral Valve Retractor System**

- Universal Self-retaining Heart Retractor
- Mitral Valve Repair or Replacement Surgery
- Exceptional Exposure for Right & Left Atrium

Kapp is the EXCLUSIVE Manufacturer of the ORIGINAL Cosgrove Design

**McCarthy Mini-Sternotomy Retractor**

The McCarthy Mini-Sternotomy Retractor is designed to provide excellent exposure for a variety of valve operations, Maze procedure or other intra-cardiac procedures. It is also used for mini sternotomy procedures or coronary artery bypass operations, based upon the patient’s size. The removable lift attachment allows optimal exposure for valve procedures.

- Mounted on a 5 inch modified chest spreader
- Small, durable, with unique smaller blades for ease of access and retracting for either proximal or distal mini-sternotomy procedures
- Provides optimal surgical exposure
- Optional CO2 tubing clip can be attached at any point along the rear bar

**Gillinov Self-Retaining Maze Retractor**

The Gillinov Self-Retaining Maze Retractor/attachment is designed to provide exposure of the pulmonary veins and atrial appendage during the Maze procedure or operations for atrial fibrillation that include pulmonary vein ablation. The visualization of these structures is greatly enhanced with this retractor.

- Mounted on a 5 inch modified chest spreader
- Small, durable, with unique smaller blades for ease of access and retracting for either proximal or distal mini-sternotomy procedures
- Provides optimal surgical exposure
- Optional CO2 tubing clip can be attached at any point along the rear bar

---

Visit Kapp Surgical at
*The AATS Annual Meeting – Booth 1732*

www.KappSurgical.com
Celebrating excellence at the Annual Meeting

Sunday’s Plenary Session was a chance to highlight two esteemed members of the cardiothoracic community for their excellence and commitment to the field. The AATS Lifetime Achievement Award was bestowed upon Michael Mack (Baylor Scott & White The Heart Hospital - Plano, TX, USA), while Joel Cooper (Hospital of The University of Pennsylvania, PA, USA) was given the Scientific Achievement Award. Congratulations go to Dr. Mack and Dr. Cooper in receiving these honors.

“This year’s awardee Dr. Michael Mack has had a truly profound impact on the direction of our specialty. He’s a visionary in the transcatheter valve space, and very, very importantly, has collaborated effectively with our cardiology colleagues and counterparts to firmly establish the place of surgeons in this space, and advance the concept of the heart team as a standard of care.”

Thoralf M. Sundt, III

“I’d like to thank the nominating committee and the Association for this prestigious award. In looking back over the nine previous recipients, I’m truly humbled to be considered in their ranks. This truly is the capstone of my career.”

Michael Mack

“This award serves to honour individuals who have achieved scientific contributions in the field of thoracic surgery, worthy of the highest recognition the Association can bestow. The nominating Committee and Board of Directors unanimously supported the nomination of Dr. Joel Cooper for this incredibly deserving award.”

Thoralf M. Sundt, III

“Thank you to Thoralf and the Association. I was notified recently that I was to receive this very distinguished award, and I started to think how could I express my gratitude, and my thoughts immediately were flooded with just so many wonderful memories of the last 50 years, and of all the people who contributed to this ... I want to thank all of those who participated, and of course the Association for this very distinguished award.”

Joel Cooper

Vision. Leadership. Scholarship.

Clinical Trials Methods Course

Save the Date
November 17–19, 2022
JB Duke Hotel
Durham, NC, USA

For more information visit aats.org/clinicaltrials

Program Directors
David H. Harpole, Jr.
Marco A. Zenati
Visit us at booth #807 and see what’s missing in your CABG surgeries

www.medistim.com
Some of the newest developments and innovations are being showcased at this year’s AATS meeting, which is focused on the latest advances in cardiac surgery and related fields. Surgeons are innovators by nature, and over the past two years, there have been significant advances in surgical techniques and technologies. The 102nd Annual Meeting is populated with world-famous names in the field of cardiovascular surgery, including Shaf Keshavjee, who was the 2022 president of the AATS. Keshavjee underscored the importance of surgical innovation and said that it is with great pleasure that he welcomes the newest developments and innovations.

As we embark on this 102nd Annual Meeting, it is evident that there is a lack of recognition that CABG can markedly reduce the risk of lung cancer. This is in contrast to the interpretation of CABG benefits that continue to accelerate beyond those found in the landmark Veterans Affairs Cooperative Study. The quality of the Annual Meeting is consistently demonstrated by the expert panelists and their presentations.

The first day of the AATS 102nd Annual Meeting saw a full calendar of lectures and discussions, and the second day was equally packed with important events. The leadership and guidance of the AATS are deeply imbedded in the culture of surgeons, and it is apparent that surgeons are innovators by nature. The meeting is orchestrated to provide opportunities for surgeons to catch up with their friends and to discuss the most important discussion points of the day.
103rd Annual Meeting

Save the Date

May 6-9, 2023
Los Angeles Convention Center
Los Angeles, CA, USA

President
Yolonda L. Colson